
FDA Releases Guidance on Labeling
The agency provides recommendations for submitting proposed labeling with abbreviated new drug applications.
FDA issued
In the guidance, FDA explains the agency’s “interpretation of the regulatory provision related to the submission of copies of applicants’ proposed labeling in ANDAs and clarifies that OGD will accept draft labeling and does not require the submission of final printed labeling (FPL) in order to approve an ANDA.” The guidance supersedes the “Acceptability of Draft Labeling to Support a Tentative Approval” section of OGD’s August 4, 1993, letter to industry and also supersedes the statement in the preamble of FDA’s proposed rule, “Abbreviated New Drug Applications and 505(b)(2) Applications,” that “final printed labeling is required as a condition of approval [of ANDAs].”
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.